Translation of "Intermittent claudication" in German

The population was old and suffered from intermittent claudication.

Intermittent claudication is the cramp-like pain in your legs when you walk and is caused by insufficient blood supply in your legs.

Intermittent claudication is caused by plaque formation within the leg arteries.

This can relieve headaches and intermittent claudication.

Therefore, arteriosclerosis in the legs is also known as intermittent claudication .

Pletal is a medication used for reducing attacks of intermittent claudication.

Glycine Propionyl L-Carnitine (GPLC) is used to alleviate intermittent claudication and blood flow issues.

This includes diseases such as intermittent claudication, varicose veins, arteriosclerosis, circulatory disorders or thromboses.

Pletal Cilostazol Pletal is a medication used for reducing attacks of intermittent claudication.

On 22 March 2013 the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) recommended that the use of cilostazol-containing medicines in the treatment of intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and affects the ability to walk - should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.

The Committee concluded that the benefit-risk balance of nicergoline containing products is not favourable pursuant to Article 116 of Directive 2001/83/EC for symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia), for ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II), for ancillary treatment of Raynaud's syndrome, for ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin, for acute retinopathies of vascular origin and for prophylaxis of migraine headache.

Common peripheral arterial occlusive disease, peripheral ischaemia, peripheral artery stenosis, intermittent claudication, deep vein thrombosis, hot flush, flushing

Overall, the group was of the view that for a small group of patients with low risk of cardiovascular co-morbidities, limiting intermittent claudication who cannot manage initial exercise rehabilitation, or who are unsuitable for revascularisation, this drug may have a role.

Cilostazol is a medicine that is used to improve walking distance in patients who have intermittent claudication due to peripheral arterial obstructive disease (obstruction and narrowing of the arteries of the limbs, leading to reduced blood flow).

Cilostazol should be initiated by physicians experienced in the management of intermittent claudication (see also section 4.4).

The efficacy of cilostazol has been evaluated in 14 clinical trials which enrolled more than 4000 intermittent claudication (IC) patients.

The experts were of the view that cilostazol has a beneficial effect in patients with limiting intermittent claudication who cannot manage an exercise program in getting such patients over “the first hurdle” that would then allow them to continue progression of their walking distance through exercise.

The Committee concluded that the benefit-risk balance of cilostazol products for the improvement of the maximal walking distance and maximal pain-free walking distances in patients with intermittent claudication (IC), who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II) remains positive under normal conditions of use, subject to restrictions, warning, changes to the product information and risk minimisation measures agreed.

Also, cilostazol should only be initiated by physicians experienced in the management of intermittent claudication after suitability of treatment with cilostazol has been carefully considered, alongside other treatment options such a revascularisation.

Various indications previously registered across the EU were deleted and the indication was restricted to the Symptomatic treatment of chronic peripheral vascular disease (stage 2) (intermittent claudication), bringing it in line with the French SmPC.

In total, 1,439 patients with intermittent claudication and no heart failure have been treated with cilostazol or placebo for up to three years.

Data relating to quality of life assessments and responder analyses was considered in the assessment as these data give some insight into the issue of the clinical relevance of the treatment effect, which is complicated by the fact that patients are likely to have different levels of benefit depending on the severity of their intermittent claudication (IC) symptoms.

However, the CHMP considered whether some of these studies could be used in support of the indication “ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II)”.

For the indication “ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II)” no data were submitted and as a result was considered as unsupported by the CHMP.

Drugs influencing peripheral haemodynamics, whether acting on the vessel wall, the blood itself or in other ways, are commonly marketed for the relief of intermittent claudication, rest pain or symptoms related to vasospasm.

Alert, ambulatory outpatients with stable intermittent claudication, generally at a non-advanced stage of the chronic arterial disease, will be selected.